237 related articles for article (PubMed ID: 34611284)
1. Enhancing adoptive CD8 T cell therapy by systemic delivery of tumor associated antigens.
Jæhger DE; Hübbe ML; Kræmer MK; Clergeaud G; Olsen AV; Stavnsbjerg C; Wiinholt MN; Kjær A; Henriksen JR; Hansen AE; Andresen TL
Sci Rep; 2021 Oct; 11(1):19794. PubMed ID: 34611284
[TBL] [Abstract][Full Text] [Related]
2. Potent immunotherapy against well-established thymoma using adoptively transferred transgene IL-6-engineered dendritic cell-stimulated CD8+ T-cells with prolonged survival and enhanced cytotoxicity.
Kalyanasundaram Bhanumathy K; Zhang B; Xie Y; Xu A; Tan X; Xiang J
J Gene Med; 2015; 17(8-9):153-60. PubMed ID: 26212685
[TBL] [Abstract][Full Text] [Related]
3. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
4. Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141
Huang J; Zhou J; Ghinnagow R; Seki T; Iketani S; Soulard D; Paczkowski P; Tsuji Y; MacKay S; Cruz LJ; Trottein F; Tsuji M
Front Immunol; 2020; 11():2043. PubMed ID: 32973811
[TBL] [Abstract][Full Text] [Related]
5. TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion.
Shakiba M; Zumbo P; Espinosa-Carrasco G; Menocal L; Dündar F; Carson SE; Bruno EM; Sanchez-Rivera FJ; Lowe SW; Camara S; Koche RP; Reuter VP; Socci ND; Whitlock B; Tamzalit F; Huse M; Hellmann MD; Wells DK; Defranoux NA; Betel D; Philip M; Schietinger A
J Exp Med; 2022 Feb; 219(2):. PubMed ID: 34935874
[TBL] [Abstract][Full Text] [Related]
6. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
7. Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade.
Hübbe ML; Jæhger DE; Andresen TL; Andersen MH
Front Immunol; 2020; 11():578349. PubMed ID: 33101304
[TBL] [Abstract][Full Text] [Related]
8. Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells.
Dovedi SJ; Lipowska-Bhalla G; Beers SA; Cheadle EJ; Mu L; Glennie MJ; Illidge TM; Honeychurch J
Cancer Immunol Res; 2016 Jul; 4(7):621-630. PubMed ID: 27241845
[TBL] [Abstract][Full Text] [Related]
9. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
Li Y; Liu S; Hernandez J; Vence L; Hwu P; Radvanyi L
J Immunol; 2010 Jan; 184(1):452-65. PubMed ID: 19949105
[TBL] [Abstract][Full Text] [Related]
10. Enhanced stimulation of anti-ovarian cancer CD8(+) T cells by dendritic cells loaded with nanoparticle encapsulated tumor antigen.
Hanlon DJ; Aldo PB; Devine L; Alvero AB; Engberg AK; Edelson R; Mor G
Am J Reprod Immunol; 2011 Jun; 65(6):597-609. PubMed ID: 21241402
[TBL] [Abstract][Full Text] [Related]
11. 4-1BB-based isolation and expansion of CD8+ T cells specific for self-tumor and non-self-tumor antigens for adoptive T-cell therapy.
Choi BK; Lee SC; Lee MJ; Kim YH; Kim YW; Ryu KW; Lee JH; Shin SM; Lee SH; Suzuki S; Oh HS; Kim CH; Lee DG; Hwang SH; Yu EM; Lee IO; Kwon BS
J Immunother; 2014 May; 37(4):225-36. PubMed ID: 24714356
[TBL] [Abstract][Full Text] [Related]
12. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
Cancel JC; Crozat K; Dalod M; Mattiuz R
Front Immunol; 2019; 10():9. PubMed ID: 30809220
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-7 Modulates Anti-Tumor CD8+ T Cell Responses via Its Action on Host Cells.
Deiser K; Stoycheva D; Bank U; Blankenstein T; Schüler T
PLoS One; 2016; 11(7):e0159690. PubMed ID: 27447484
[TBL] [Abstract][Full Text] [Related]
14. Targeting dendritic cells with antigen-containing liposomes: antitumour immunity.
Altin JG; van Broekhoven CL; Parish CR
Expert Opin Biol Ther; 2004 Nov; 4(11):1735-47. PubMed ID: 15500402
[TBL] [Abstract][Full Text] [Related]
15. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism.
Xu S; Koski GK; Faries M; Bedrosian I; Mick R; Maeurer M; Cheever MA; Cohen PA; Czerniecki BJ
J Immunol; 2003 Sep; 171(5):2251-61. PubMed ID: 12928369
[TBL] [Abstract][Full Text] [Related]
16. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
17. Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.
Wei J; Waithman J; Lata R; Mifsud NA; Cebon J; Kay T; Smyth MJ; Sadler AJ; Chen W
J Immunol; 2010 Nov; 185(10):6013-22. PubMed ID: 20956347
[TBL] [Abstract][Full Text] [Related]
18. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
19. Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion.
Wang LX; Chen BG; Plautz GE
J Immunol; 2002 Sep; 169(6):3314-20. PubMed ID: 12218152
[TBL] [Abstract][Full Text] [Related]
20. Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens.
Pathangey LB; McCurry DB; Gendler SJ; Dominguez AL; Gorman JE; Pathangey G; Mihalik LA; Dang Y; Disis ML; Cohen PA
Oncotarget; 2017 Feb; 8(7):10785-10808. PubMed ID: 27974697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
